South Korea Pulmonary Arterial Hypertension Market Outlook

south korea’s pulmonary arterial hypertension (pah) market has grown significantly since 2018 and is projected to continue to expand in the coming years. the prevalence of pah in south korea is estimated to be 0.11%, with the overall prevalence of pulmonary hypertension estimated to be around 1.3%. the major cause of pah in south korea is left-heart disease, such as mitral valve disease or mitral stenosis. the most common treatment for pah in south korea is bosentan, which has been approved by the ministry of food and drug safety (mfds). this drug is the most widely used for pah treatment in the country, and has demonstrated efficacy in reducing mortality rates and improving quality of life of patients. other drugs available in the market include ambrisentan, iloprost, selexipag, and sildenafil. in recent years, there has been an increase in the number of pah patients seeking medical attention at hospitals. this has been due to the rising awareness about pah and growing accessibility of diagnosis and treatment by healthcare professionals. the government is also increasingly promoting methods to diagnose and manage the disease at an earlier stage. in addition, there is increasing recognition about the need to provide affordable and efficient treatments to pah patients in the country. since 2018, the government has started to provide financial support for patients receiving bosentan, selexipag and ambrisentan treatments. this has reduced the financial burden on pah patients and has enabled access to better healthcare services. finally, south korea is witnessing an increasing number of research and development activities to discover novel therapies for pah. this includes phase 1 and 2 clinical trials being conducted in the country. the results of such trials could lead to the availability of new medicines with improved efficacy and efficacy profiles. thus, south korea pulmonary arterial hypertension market is expected to continue to expand in the coming years, supported by the increasing prevalence of disease, growing access to healthcare services and availability of novel treatments.